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Abstract 
Background: An artificial pancreas with insulin and glucagon delivery has the 
potential to reduce the risk of hypo- and hyperglycemia in people with type 1 
diabetes. However, a maximum dose of glucagon of 1mg/day is recommended, 
potentially still requiring rescue carbohydrates in some situations. This work presents 
a parallel control structure with intrinsic insulin, glucagon and rescue carbohydrates 
coordination to overcome glucagon limitations when needed. 
Methods: The coordinated controller that combines insulin, glucagon and rescue 
carbohydrate suggestions (DH-CCCHO) was compared with the insulin and glucagon 
delivery coordinated controller (DH-CC). The impact of carbohydrate quantization for 
practical delivery was also assessed. An in silico study using the UVA-Padova 
simulator, extended to include exercise and various sources of variability, was 
performed. 
Results: DH-CC and DH-CC-CHO performed similarly with regard to mean glucose 
(126.25[123.43;130.73] vs 127.92[123.99;132.97] mg/dL, p=0.088), time in range 
(93.04[90.00;95.92] vs 92.91[90.05;95.75]%, p=0.508), time above 180 mg/dL 
(4.94[2.72;7.53] vs 4.99[2.93;7.24]%, p=0.966), time below 70mg/dL (0.61[0.09;1.75] 
vs 0.96[0.23;2.17]%, p=0.1364), insulin delivery (43.50[38.68;51.75] vs 
42.86[38.58;51.36] U/day, p=0.383), and glucagon delivery (0.75[0.40;1.83] vs 
0.76[0.43;0.99] mg/day, p=0.407). Time below 54mg/dL was different (0.00[0.00;0.05] 
vs 0.00[0.00;0.16]%, p=0.036), although non-clinically significant. This was due to the 
carbs quantization effect in a specific patient, since when carbs were not quantized, 
no statistical difference was found (0.00[0.00;0.05] vs 0.00[0.00;0.00]%, p=0.265). 
Conclusions: The new strategy of automatic rescue carbohydrates suggestion in 
coordination with insulin and glucagon delivery to overcome constraints on daily 
glucagon delivery was successfully evaluated in an in silico proof of concept. 
 
Introduction 
An artificial pancreas (AP) is an automated insulin delivery system aiming at the 
improvement of glucose control in people with type 1 diabetes (T1D)1. A single-
hormone AP (SHAP) consists in a continuous glucose monitor, an insulin pump and a 
control algorithm that modulates insulin infusion quasi-continuously. Dual-hormone AP 
systems (DHAP) also introduce glucagon infusion as control action to compensate the 
uni-directional effect of insulin on glucose. Recent developments on stable soluble 
glucagon formulations2  are paving the way to such systems although no commercial 
formulation is yet available. However, long-term safety of glucagon delivery is unknown.  
 
Since demonstration of feasibility of DHAP systems in humans3, several studies have 
targeted head-to-head comparisons between SHAP and DHAP systems4-10. A recent 
review of results11 concluded that: during nocturnal period SHAP was enough for a 
good glucose control while DHAP proved superior performance in reduction of 
hypoglycemia overall and during exercise; benefits in post-prandial control, reduction 
of severe hypoglycemia and mean glucose are unclear. In the 4-arm 4-day outpatient 
study with three moderate-intensity aerobic exercise sessions by Castle et al.5, DHAP 
achieved lower time in hypoglycemia during exercise compared to SHAP and 
predictive-low-glucose-suspend, and similar to standard care where pre-exercise 
insulin adjustments were allowed. However, despite the use of glucagon and 
wearables to detect exercise, hypoglycemia was still present (1.3%(1.0) overall and 
3.4%(4.5) during exercise; mean(SD)). 
 
Current DHAP systems are based on an insulin controller and a glucagon controller 
which is activated in certain circumstances in order to initiate the counterregulatory 
action. These independent control loops may create unwanted interactions among 
hormones delivery reducing effectiveness. Besides, an excess of plasma insulin has 
been found to reduce effectiveness of glucagon microboluses by El Youssef et al.12, 
which does not support the design of DHAP systems with aggressive insulin infusion 
considering the availability of glucagon to compensate the increased risk of 
hypoglycemia. Indeed, physiologically there is a coordination between insulin and 
glucagon secretion13. On the one hand, an increment in plasma insulin levels produces 
a suppression of glucagon secretion in T1D patients; and a decrement in insulin levels 
together with low plasma glucose concentration stimulates glucagon secretion14. On 
the other hand, alpha cells anticipate the possible hyperglycemic rebounds due to the 
glucagon secretion by means of beta cell sensitization15.  
 
Motivated by this paracrine communication, control algorithms incorporating 
coordinated insulin and glucagon delivery have been investigated. In Herrero et al.16, 
potentiation of insulin by glucagon was incorporated in the Imperial College AP system, 
reporting in silico a reduction in hyperglycemia without increased hypoglycemia. In 
Bondia et al.17,18 a control algorithm with intrinsic coordination based on a collaborative 
parallel control formulation was first introduced. Thorough in silico evaluation showed 
the benefit of coordination with lower glucagon delivery, although room for 
improvement under exercise was identified19. Further refinements incorporating Sliding 
Mode Reference Conditioning (SMRC) techniques for insulin-on-board limitation were 
carried out in Moscardó20 (see Section 7.6). When compared to the original algorithm19, 
the refined controller showed improvements in percentage of time in target 
(92.98%(3.24) vs. 91.56%(3.42)) and time in hypoglycemia (1.45%(2.01) vs. 
3.40%(2.92)) in a two-week scenario with daily 60-min exercise sessions. Nevertheless, 
some few patients required glucagon delivery higher than 1 mg/day (0.75 mg/day 
[0.40;1.83]; median[25-75 percentiles]). 
 
In this work, parallel control structure (DH-CC) is further exploited to compensate such 
excess of glucagon need in some patients with the integration of rescue carbohydrate 
as an alternative control route (DH-CC-CHO). Parallel control computes a virtual 
control action (control effort) that later is distributed into the different control actions to 
get a combined effect equal to the needed control effort. This gives rise to a flexible 
control structure where different configurations combining insulin, automatic rescue 
carbs suggestions and glucagon can be designed by reconfiguring the distribution 
logics. DH-CC and DH-CC-CHO are compared to analyze the benefits of this new 
proposal during the challenging exercise scenario in Moscardó et al. 19,20. 
 
Methods 
Coordinated parallel control DHAP including rescue carbohydrates 
Coordinated control techniques for multiple-input-single-output systems have been 
developed in different ways in literature21. Of interest is the concept of habituating 
control22,23, where control actions are classified as “slow and cheap” (primary) and “fast 
and expensive” (secondary). In a DHAP, the “fast and expensive” control action can be 
associated to glucagon, with a faster subcutaneous PK/PD, although its delivery must 
be restricted to 1mg/day due to the possible side effects such as nausea, vomiting and 
headache24; instead, the “slow and cheap” action is associated to insulin. Additional 
inputs can also overcome saturation problems of the primary action contributing with 
the additional control effort not able to be provided by the latter. 
 
These concepts can be casted into a parallel control structure where a main controller 
computes the needed control effort (virtual control action), which is later distributed by 
a divisor among the available control actions, giving rise to intrinsic coordination25. This 
technique was applied to derive a DHAP coordinating insulin and glucagon delivery19,20 
(see diagram in black in Figure 1). In this controller, the divisor was designed so that 
glucagon acts as a secondary control action when insulin delivery is below a given 
threshold (set in this case to 75% of basal insulin infusion) for hypoglycemia mitigation. 
 
However, in some occasions the delivery of glucagon is not enough to prevent 
hypoglycemia, as revealed by the need of rescue carbohydrates in DHAP clinical 
studies, or an overdelivery of glucagon beyond the limit of 1mg/day may result. In these 
cases, integration of automatic suggestion of rescue carbohydrates into a DHAP can 
overcome these limitations. To this end, a third control action can be incorporated into 
the above-described parallel control strategy (branch highlighted in red in Figure 1), 
considering ideal administration of rescue carbohydrate, with a posteriori quantization 
for practical dosing by the patient. In this work, constraint on the maximum delivery of 
glucagon per day is addressed through the replacement of glucagon as a secondary 
action by rescue carbohydrate when the accumulated glucagon in a given 24-h time 
window is greater than the total daily dose restriction imposed. 
 
In the following the proposed controller is described. Consider the system linearization 
∆𝐺 𝑠 = 𝛼𝐻' 𝑠 ∆𝑢 𝑠 + 𝛽𝐻+ 𝑠 ∆𝜔 𝑠 + 𝜀𝐻. 𝑠 ∆𝑟 𝑠 + 𝑑(𝑠),    (1) 
where ∆G(s) is the deviation of plasma glucose concentration from the equilibrium 
value G*; ∆u(s) is the deviation of insulin infusion from its equilibrium value u*; ∆ω(s) 
is the deviation of glucagon infusion from the equilibrium value ω*, which is null; ∆r(s) 
is the fast-acting rescue carbohydrate intake and d(s) a disturbance (e.g., glycemic 
effect of meal and exercise). Transfer functions 𝐻'(𝑠) , 𝐻+(𝑠) , and 𝐻.(𝑠)  are the 
linearized plants representing the glycemic effect of insulin, glucagon and rescue 
carbohydrate respectively, with 𝐻' 0 = 𝐻+ 0 = 𝐻. 0 = 1.  Thus, gains  𝛼, 𝛽  and 𝜀 
correspond to sensitivities to insulin, glucagon and rescue carbohydrate, respectively, 
which will be patient-dependent. Remark that 𝐻'(𝑠)  and 𝐻.(𝑠)  will have a slower 
dynamics than 𝐻+(𝑠) because of faster glucagon PK/PD. 
 
In the absence of disturbance, the plant with faster dynamics, i.e., H2(s), is factorized 
as follows: 
∆𝐺 𝑠 = 𝐻+(𝑠) 𝛼
89 :
8; :
∆𝑢 𝑠 + 𝛽∆𝜔 𝑠 + 𝜀 8< :
8; :
∆𝑟 𝑠 ,    (2) 
 
leading to the following definition of the control effort ∆𝜇 (new virtual control action) and 
its primary/secondary actions, ∆𝜐', ∆𝜐+, and ∆𝜐.: 
∆𝜇 𝑠 ≔ ∆𝜐' 𝑠 + ∆𝜐+ 𝑠 + ∆𝜐. 𝑠 ,      (3) 
∆𝜐' 𝑠 ≔ 𝛼
89 :
8; :
∆𝑢 𝑠 ,        (4) 
∆𝜐+ 𝑠 ≔ 𝛽∆𝜔 𝑠 ,        (5) 
∆𝜐. 𝑠 ≔ 𝜀
8< :
8; :
∆𝑟 𝑠 .        (6) 
Remark that now equation (2) can be expressed as a single-input-single-output (SISO) 
system in terms of the new virtual control action: 
∆𝐺 𝑠 = 𝐻+(𝑠)∆𝜇 𝑠 ,        (7) 
where no saturation constraints apply to ∆𝜇(𝑠), as compared to insulin, glucagon and 
rescue carbohydrate control actions, which must be non-negative. A controller 𝐶(𝑠) 





.        (8) 
The controller 𝐶 𝑠 	will be denoted as “master controller” in the parallel control structure. 
Here, a PD controller is considered 
𝐶 𝑠 = 𝑘G(1 + 𝑇I𝑠),        (9) 
where 𝑘G is the proportional gain and 𝑇I is the derivative time. The control action ∆𝜇(𝑠) 
computed by (9) can be distributed in terms of  ∆𝜐', ∆𝜐+, and ∆𝜐. with consideration of 
the constraint imposed by (3). Then, by inverting equations (4)-(6), the final insulin, 
glucagon and (ideal) rescue carbohydrate actions can be obtained: 





∆𝜐'(𝑠),        (10) 
∆𝜔 𝑠 = '
L
∆𝜐+(𝑠),        (11) 





∆𝜐.(𝑠),       (12) 
𝑢 𝑠 = ∆𝑢 𝑠 + 𝑢∗,         (13) 
𝜔 𝑠 = ∆𝜔 𝑠 ,         (14) 
𝑟 𝑠 = ∆𝑟 𝑠 .         (15) 
        
A key element is the design of the divisor that distributes the virtual control action ∆𝜇 𝑠     
fulfilling (3). The following distribution is considered here:   
∆𝜐' 𝑠 = (1 − 𝛾')∆𝜇(𝑠),                   (16) 
∆𝜐+ 𝑠 = 𝛾'𝛾+∆𝜇 𝑠 ,                   (17) 
∆𝜐. 𝑠 = 𝛾' 1 − 𝛾+ ∆𝜇 𝑠 .                  (18)
          
where 𝛾'𝜖[0,1] is the design parameter to fix the relative weight of the control actions 
∆𝜐' and counterregulatory actions (∆𝜐+, ∆𝜐.); and  𝛾+𝜖[0,1] is the design parameter to 
fix the relative weight of the control actions ∆𝜐+and ∆𝜐.  determining the degree of 
collaboration between them.  
 
Counterregulatory actions are designed to be delivered only when insulin infusion is 
below a certain threshold, 𝑢TU . Regarding glucagon and rescue carbohydrates, the 
latter will be triggered when the accumulated glucagon from the start of the considered 
24-h time window is higher than 1mg. Thus, the following divisors are defined as: 
𝛾' =
1 𝑢 𝑡 	≤ 𝑢TU
0 𝑢 𝑡 > 𝑢TU
        (19) 
𝛾+ =
1 𝜔(𝜏)𝑑𝜏TTKTZ 	≤ 1	𝑚𝑔
0 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
       (20) 
 
where 𝑢 𝑡 	is the would-be insulin infusion if directing the total control effort through the 
insulin input channel, i.e., ∆𝜐' 𝑠 = 	∆𝜇 𝑠 . This means that if the control effort can be 
supplied by insulin, relative to the defined threshold 𝑢TU , then no counterregulatory 
action is triggered. Notice that the time that define the start of each 24-h time window 
(𝑡b)	is customizable.   
 
The switching due to equations (19)-(20) does not affect the closed-loop transfer 
function. Therefore, the closed-loop transfer function remains unaltered and it will be 
stable by design conditions on 𝐶 𝑠 .     
          
An SMRC loop26,27 is also considered for the limitation of insulin-on-board (IOB). 
Remark that this does not modify the stability of the closed-loop system since it acts 
on the glucose reference. Here, IOB is represented by subcutaneous insulin 
compartments in Hovorka model28, 𝑆' 𝑡 	and 𝑆+ 𝑡 , giving rise to the following definition
  
𝐼𝑂𝐵 𝑡 ≔ 𝑆' 𝑡 + 𝑆+ 𝑡         (21) 
        
Given the system in Figure 1 and an upper limit of IOB, 𝐼𝑂𝐵ghi 𝑡 , the  set  
≔ 𝑥 𝑡 𝐼𝑂𝐵 𝑇 	≤ 𝐼𝑂𝐵ghi(𝑡)}, where 𝑥 𝑡  denotes the system state, is invariant for 
the discontinuous signal 𝜔:  
𝜔(𝑡) = 𝜔
D 𝑖𝑓	𝜎no 𝑡 > 0
0 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒,        (22) 
𝜎no 𝑡 ≔ 𝐼𝑂𝐵 𝑡 − 𝐼𝑂𝐵ghi 𝑡 + 	 𝜏p 𝐼𝑂𝐵 p 𝑡 − 𝐼𝑂𝐵ghi
(p)BK'
pq' ,                (23) 
where 𝜔D > 0 is large enough and l is the relative degree between the output 𝐼𝑂𝐵 𝑡  
and the input 𝜔 𝑡 , (i) is the i-th derivative, and 𝜏p  are gains to fit. Signal 𝜔 𝑡  will 




= 𝜆𝐺xyz{ 𝑡 + 𝜆(𝐺xyz 𝑡 + 𝜔 𝑡 ),                     (24) 
where 𝐺xyz is the original glucose reference (constant here), 𝐺xyz{  is the conditioned 
reference, and defines the cut-off frequency of the filter. Relative degree 𝑙 in (23) will 
be 2, as determined by the relative degree of the filter (24) and the relative degree of 
the IOB predictor (21), since the same structure is obtained for 𝐻'(𝑠)  and 𝐻+(𝑠) 
describing insulin and glucagon PK/PD. 
   
Rescue carbohydrate quantization 
Rescue carbohydrate control action is quantized in rescue events of 15g for practical 
administration by the patient. The event will be triggered only when an accumulated 
rescue carbohydrate action over half this dose is required, and will not be triggered 
again unless the dose administered in excess was required, repeating the strategy. 
 
The quantized rescue carbohydrate control action, 𝑢C8}(𝑡), is then given by 
𝑢C8}(𝑡) =
15 𝑓(𝑡) 	≥ 7.5
0 𝑓 𝑡 < 7.5,       (25) 
where 
𝑓 𝑡 = (𝑟 𝜏 + 𝑔(𝜏))𝑑𝜏Tb ,       (26) 
𝑔(𝑡) =
−15 𝑓(𝑡) 	≥ 7.5
0 𝑓 𝑡 < 7.5,       (27) 
A value of 7.5g in (25) was used similarly to Beneyto et al.29, although other values 
could be considered. 
 
Controllers tuning 
Table 1 shows the parameters values for the DHAP without and with rescue 
carbohydrates. As said before, the DHCC-CHO is an improvement of the DH-CC 
structure by means of the addition of a third loop. Thus, both structures share the tuning 
of the master controller parameters, which was manually tuned to achieve the best 
possible glycemic outcomes (i.e. percentage of time in range [70,180] mg/dL and 
percentage of time below target). 
 
For all the evaluated subjects, parameters were fixed to the same value except 
parameters 𝛼, 𝛽, 𝜀  and 𝐼𝑂𝐵ghi.  Parameters 𝛼, 𝛽  and 𝜀  were individualized for each 
patient following an identification procedure based on the impulse response for a set 
of bolus doses. Parameter 𝐼𝑂𝐵ghi was time invariant and defined as 30% above basal 
IOB for each patient, 𝐼𝑂𝐵∗. Lastly, the effect of the parameter 𝑢TU  on the controller 
performance was evaluated in Moscardó20 (see Appendix C therein) in order to 
determine the optimal switch condition for CC. Threshold values 0, 0.25𝑢∗, 0.5𝑢∗, and 
0.75𝑢∗ were considered and outcome metrics assessed in three different scenarios 
(with meal, snack and exercise disturbances) for the average patient. Results are 
summarized in Figure 2. The best result was obtained for 𝑢TU = 0.75𝑢∗ with lower time 
in hypoglycemia without compromising time in range and without glucagon over-
delivery. To ease tuning, this value will be considered populational for the whole cohort.  
 
In silico evaluations 
The educational version of the UVA/Padova simulator30 with the addition of the 
exercise model in Schiavon et al.31 and intra-day and intra-subject variability was used 
to assess and compare the above control structures. 
 
Intra-day variability was incorporated to the simulator by modifying some of the 
parameters: meal variability was emulated by introducing meal-size variability 
(CV=10%), meal-time variability (STD=20) and uncertainty in the carbohydrate 
estimation (uniform distribution between -30% and +40%). Variability of meal 
absorption rate (𝑘h:) and carbohydrate bioavailability (𝑓) were considered to be ±30% 
and ±10% respectively. For intra-day meal variability, the 11 meal model parameters 
from the cohort were randomly assigned at each meal intake. 
 
To emulate intra-subject variability, insulin absorption model parameters 
𝑘I, 𝑘h', 𝑘h+ 	 were varied ±30%. Insulin sensitivity parameters (𝑉gi, 𝑘G.)  were 
assumed to change along the day following a sinusoidal pattern, Finally, the variability 
into exercise was added by modifying the starting time (STD= 20 min), the exercise 
intensity (CV=10), and the duration (CV= 10). 
 
The scenario considered meal and exercise. The selected daily pattern of carbohydrate 
doses was 7am (50g), 1pm (80g), 8pm (60g), and the daily exercise started at 3pm 
with a duration of 60 minutes and an intensity of 50%. 
 
A two-week scenario duration was used to compare the DH-CC with DH-CC-CHO 
configurations in 100 adults. The subjects are based on the 10 adults that are available 
in the educational version of the UVA/Padova simulator, with 10 repetitions each 
getting different instances of variability. Moreover, the chosen basal insulin infusion 
rates, 𝑢∗, were the ones provided by the simulator for each subject. 
 
Data analysis 
In order to carry out the comparison between both proposed control structures, the 
standard glycemic control metrics32  were used: mean blood glucose (MG); percentage 
time in target range [70,180] mg/dL (TIR); percentage time below target (<70mg/dL 
and <54mg/dL); percentage time above target (>180 mg/dL); daily average of insulin 
delivered in units of insulin (INS); and daily average of glucagon delivered in mg 
(GGON). Statistical differences were assessed by the Non-Parametric Wilcoxon 
signed-rank test due to non-normality of the data. Significant p-value was 0.05. 
 
Results and discussion 
 
Table 2 shows the results corresponding to the cohort analyzed for both control 
structures, DH-CC (column 1) and DH-CC-CHO (column 2). For a better analysis, 
configurations of DH-CC-CHO with no quantization of rescue carbohydrate (column 3) 
and DH-CC with limitation of glucagon to 1mg/day without additional carbs (column 4) 
are also presented. 
 
Performance of DH-CC and DH-CC-CHO was similar in terms of mean glucose 
(p=0.088), time in range (p=0.508), time above 180 mg/dL (p=0.966), time below 
70mg/dL (p=0.1364), insulin delivery (p=0.383), and glucagon delivery (p=0.407). For 
DH-CC, glucagon doses higher than 1mg/day were only required by 30 adults (derived 
from the same 3 patients in the original 10-adult cohort) who seem to be more glucagon 
resistant. Statistically significant difference in time below 54 mg/dL was found 
(p=0.036), although median time was 0% and 75-percentile 0.16% with low clinical 
significance. All events were mainly related to the same patient. This difference was 
not found in case of DH-CC-CHO (non-quantized) (p=0.265), where ideal continuous 
administration of carbs is considered, which indicates that rescue carbohydrate 
quantization might be the responsible for the above difference, especially for that 
patient. However, no statistical difference was found in any metrics between DH-CC-
CHO and DH-CC-CHO (non-quantized) concluding no major impact of the quantization 
process in the system performance. Limitation of glucagon delivery to 1mg/day without 
additional carb intake to complete the required control effort (column 4 in Table 2) 
yielded higher time below 70mg/dL and 54mg/dL, with statistical significance with all 
the other three configurations analyzed. If studies where delivered glucagon was 
greater than 1mg/day for DH-CC are analyzed (n=30), the addition of rescue CHO (DH-
CC-CHO) implied a glucagon delivery lower than 1mg/day (0.997 [0.997;0.998] mg/day) 
and the need of 2.04 [1.71; 2.5] CHO rescues (1 rescue=15g). 
 
Figure 3 illustrates the controllers performance of two patients where the glucagon 
limitation was needed, as compared to glucagon limitation without rescue carb intake. 
Two days instead of all 14 days are represented in order to depict better the behavior 
described by the considered approaches. It can be observed that in these patients 
limitation of glucagon delivery to 1mg/day would have provoked hypoglycemia during 
the afternoon (green dashed line), which was successfully avoided by the DH-CC-CHO 
controller (solid blue line) with the automatic suggestion of rescue carbs contributing 
with the same control effort than the needed glucagon, achieving a similar performance 
than DH-CC (dashed purple line). 
 
This proof-of-concept study demonstrates (in silico) the flexibility of the parallel control 
strategy, where different divisor strategies can be devised attending to scenario 
particularities and user preferences, besides overcoming constraints on glucagon 
delivery. For instance, glucagon has shown to be more effective in exercise scenarios 
than postprandial periods, where rescue carbohydrate can be a better option for 
hypoglycemia mitigation. Additionally, other quantization strategies for practical carb 
intake by the patient could be derived. Clinical validation supporting the in silico results 
is needed since simulations might suffer from TIR overestimation, given current clinical 




A new control strategy for a dual hormone artificial pancreas system incorporating 
automatic suggestion of rescue carbohydrates in coordination with insulin and 
glucagon delivery was presented. The method allows to select among glucagon or 
rescue carbohydrate counterregulatory action, providing the same equivalent required 
control effort as computed by a master controller, following a parallel control structure. 
Application of this strategy to overcome constraints on daily glucagon delivery was 
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Table 1. Controller parameters. The symbol † indicates a patient-dependent parameter.	
Parameters Controller configuration DH-CC DH-CC-CHO 
𝑘G 3.1350·10
-4 3.1350·10-4 
𝑇I(min) 90 90 
𝐺xyz(mg/dL) 100 100 
𝑡b - 8:00pm 
𝛼 (†) (†) 
𝛽 (†) (†) 
𝜀 (†) (†) 
𝑢TU 0.75·u* (†) 0.75·u* (†) 
𝜏 (min) 10 10 
𝜔D(mg/dL) 200 200 
𝐼𝑂𝐵ghi (U) 1.3·IOB* (†) 1.3·IOB* (†) 
 
 
Table 2. Evaluation results. Notation *i,j indicates statistically significant difference with 
respect to systems i and j (p-value <0.05). For simplicity explicit p-values are not shown. 
Data are median[25-75 percentiles]. 
	
 









































































Figure 1. Block diagram of the proposed coordinated parallel control DHAP including 
rescue carbohydrates. An external SMRC loop is also considered for insulin-on-board 





Figure 2. Effect of the threshold value 𝑢TU on percent time in range (70-180mg/dL), 
time in hypoglycemia (<70mg/dL), daily insulin delivery and daily glucagon delivery for 





Figure 3. Comparison between different controller approaches: DH-CC (dashed purple 
line), DH-CC-CHO (solid blue line) and DH-CC (glucagon ≤ 1mg/day) (dashed green 
line). Meals and exercise events are marked with triangles and stars respectively. 
 
 
 
 
